War unrest threatens medical supplies and raises fears of drug shortages

Medicine transport chains are facing increasing challenges with the escalation of military tensions in the Middle East, as the repercussions of the conflict have begun to be reflected in the movement ofAir freight, which the pharmaceutical industry relies on to transport sensitive treatments. In this context, growing concerns have emerged about the possibility of drug shortages in some markets, especially those that depend on imports to meet their needs for specialized treatments.

These concerns increase in light of the sensitive nature of a number of medicines that require rapid transportation and precise storage conditions, especially biological medicines and cancer treatments that require a continuous cold chain to maintain their effectiveness. With the disruption of some air transport routes in the region, pharmaceutical companies are forced to look for alternative ways to ensure that treatments continue to reach patients.

War disrupts drug transport routes

Military strikes and escalating tensions in the region have led to the closure or disruption of a number of vital air corridors used to transport medical shipments between Europe, Asia and the Middle East. Some airports in the Gulf constitute major logistical centers for the transit of temperature-sensitive medicines, which makes any disturbance in their operation quickly affect the movement of pharmaceutical cargo.

In light of these developments, and growing fears of drug shortages, pharmaceutical and logistics companies have begun redirecting their shipments through alternative airports or using longer transportation routes to reach their target markets. This means increased transportation time and higher shipping costs, which adds additional pressures on pharmaceutical supply chains that primarily depend on speed and accuracy in delivery, and these pressures increase especially with regard to sensitive medicines.

Sensitive medicines most at risk

Concerns are greater regarding medicines that need special transportation conditions, most notably cancer treatments and some newer biological medicines. These treatments are usually transported via air freight within precise cooling systems that ensure that temperatures remain within a specific range throughout the journey.

With the complexity of transportation in the region, some shipments may face challenges related to flight delays or changes in air routes, which raises the possibility of medicines being exposed to longer than usual transportation conditions, which threatens the possibility of medicine shortages. In this context, pharmaceutical companies are working to give priority to the most sensitive shipments to ensure their arrival to hospitals without affecting their quality. In order to overcome these challenges, companies are also moving to search for alternative paths to ensure the security of supply chains, and these efforts are combined to achieve the third goal of the Sustainable Development Goals (SDGs) related to achieving good health and well-being for patients around the world.

Searching for alternative supply routes

In an attempt to minimize the effects of the current unrest, pharmaceutical companies have begun to rely on alternative transportation routes to reach markets in the Gulf. These alternatives include using other airports in the region and then transporting the medicines by land to their final destinations, which are solutions that are usually used in emergency situations to maintain continuity of supplies.

Some companies also resorted to completely reorganizing shipping plans, by directing some flights through logistical centers in Asia or other regions outside the conflict routes. As field conditions continue to change, these operations require continuous monitoring of air traffic and airspace restrictions.

Dangers of drug shortages if disorders continue

Many countries rely on limited stocks of some specialized medicines, which makes any long delay in supplies a source of concern for the health sector. Health sector experts estimate that the available stock of some sensitive medicines may only cover several weeks or months, which explains the growing concern about the possibility of drug shortagesif disruptions in transportation continue for a longer period.

This challenge is particularly prominent in cancer treatments that are given within precise treatment programs, as the delayed arrival of the drug may lead to disruption of the course of treatment for some patients, and in some cases doctors may be forced to modify or postpone treatment plans until new supplies arrive. Under these circumstances, health authorities and pharmaceutical companies are moving to give priority to the most sensitive therapeutic shipments, while strengthening coordination between hospitals and distribution networks to ensure that essential treatments reach patients in a timely manner.

In a broader context, these challenges highlight the importance of building more resilient systems to ensure the sustainability of medicine supplies, by diversifying transportation routes, enhancing strategic stocks of vital medicines, and developing storage and distribution capabilities within health systems. This trend contributes to reducing the health sector’s vulnerability to geopolitical disturbances, and also supports the ability of health systems to continue providing treatment even in times of crisis, which enhances the concept of sustainability in the health care sector and ensures patients’ continued access to essential medicines without interruption.

In conclusion, these developments reflect the extent to which the stability of health supply chains is linked to geopolitical conditions and global trade. Medicines produced on one continent and transported across other continents to reach patients depend on complex transportation networks that require a great deal of stability and coordination.

The Earth Guards Foundation believes that ensuring the continuity of drug supplies represents an essential part of achieving sustainable development, as the stability of health supply chains is linked to enhancing the ability of health systems to provide treatment for patients in various circumstances. This comes within the framework of the third goal of the Sustainable Development Goals (SDGs), which focuses on ensuring good health and well-being for all and enhancing the ability of health systems to confront global crises and challenges.